Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

Chen, Danfeng; Jin, Duochen; Huang, Shumin; Wu, Jingyi; Xu, Mengque; Li, Tianyu; Dong, Wenxiao; Liu, Xiang; Wang, Sinan; Zhong, Weilong; Liu, Yi; Jiang, Ruihuan; Piao, Meiyu; Wang, Bangmao; Cao, Hailong

doi:10.1016/j.canlet.2019.11.019

Cited by 296 publications

(264 citation statements)

References 82 publications

Supporting

Mentioning

239

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that probiotics can affect the structure of gut microbiota and the interaction with the microbial community and the host health through different mechanisms [12,[193][194][195]. These effects are mediated by the direct or indirect action of probiotics and can involve the modulation of the immune system or that of remote organs like the brain and liver due to the production of metabolites finally localized in these organs [193,[196][197][198][199].…”

Section: Probiotic Administration Microbiota Bile Acids and Cardiovmentioning

confidence: 99%

The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

The importance of gut microbiota in health and disease is being highlighted by numerous research groups worldwide. Atherosclerosis, the leading cause of heart disease and stroke, is responsible for about 50% of all cardiovascular deaths. Recently, gut dysbiosis has been identified as a remarkable factor to be considered in the pathogenesis of cardiovascular diseases (CVDs). In this review, we briefly discuss how external factors such as dietary and physical activity habits influence host-microbiota and atherogenesis, the potential mechanisms of the influence of gut microbiota in host blood pressure and the alterations in the prevalence of those bacterial genera affecting vascular tone and the development of hypertension. We will also be examining the microbiota as a therapeutic target in the prevention of CVDs and the beneficial mechanisms of probiotic administration related to cardiovascular risks. All these new insights might lead to novel analysis and CVD therapeutics based on the microbiota.

show abstract

Section: Probiotic Administration Microbiota Bile Acids and Cardiovmentioning

confidence: 99%

The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Clostridium butyricum was used as the representative of butyrate-producing bacteria because it was one of the most commonly used butyrateproducing bacteria in clinical studies and basic science. [70][71][72][73][74] Clostridium butyricum (ATCC 19398), which was kindly provided by China General Microbiological Culture Collection Center was incubated in brain heart infusion medium at 37°C in an anaerobic environment for 24 h. And then the bacteria were harvested with centrifugation (3000 g × 5 min) and resuspended in sterile PBS at the density of 1 × 10 10 CFU/ml. Then, we collected the supernatant, filtered it through aperture filters of 0.22-μm, and then diluted it with complete culture medium.…”

Section: Cells and Bacterial Preparationmentioning

confidence: 99%

“…The treating concentration and time were selected based on our previous research. 74 The treatment lasted for 24 h and then the cells were collected for real-time PCR analysis. The relative expression of GPR43 and TNF-α was detected.…”

Section: Treatment Of Hct116 and Hct8 Cells Withmentioning

confidence: 99%

Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Nonalcoholic fatty liver disease (NAFLD) is considered to be associated with diet and gut dysbiosis. Excessive sucralose can induce gut dysbiosis and negatively affect host health. Maternal diet shapes the microbial communities of neonate and this effect continues in later life. We aimed to investigate the effects of maternal sucralose (MS) intake on the susceptibility of offspring to hepatic steatosis in adulthood. Methods: C57BL/6 pregnant mice were randomized into MS group (MS during gestation and lactation) and maternal control (MC) group (MC diet). After weaning, all offspring were fed a control diet until 8 weeks of age, and then treated with a high-fat diet (HFD) for 4 weeks. The intestinal development, mucosal barrier function, and gut microbiota were assessed in the 3-week-old offspring. Moreover, the severity of hepatic steatosis, serum biochemistry, lipid metabolism, and gut microbiota was then assessed in the 12th week. Results: MS significantly inhibited intestinal development and disrupted barrier function in 3-weekold offspring. MS also induced intestinal low-grade inflammation, significantly changed the compositions and diversity of gut microbiota including reducing butyrate-producing bacteria and cecal butyrate production with down-regulation of GPR43. Mechanically, blocking GPR43 blunted the antiinflammatory effect of one of the butyrate-producing bacteria, Clostridium butyricum in vitro. After HFD treatment, MS exacerbated hepatic steatosis, and disturbed fatty acid biosynthesis and metabolism, accompanied by inducing gut dysbiosis compared with MC group. Conclusions:MS intake inhibits intestinal development, induces gut dysbiosis in offspring through down-regulation of GPR43, and exacerbates HFD-induced hepatic steatosis in adulthood.

show abstract

“…However, C. butyricum, a butyrate-producing probiotic, can relieve intestinal inflammation, improve immune homeostasis, and inhibit CRC development in mice [109]. In addition, C. butyricum can improve the intestinal microbiota composition and suppress the Wnt/β-catenin signaling pathway, significantly inhibiting the development of CRC in Apc Min/+ mice [110].…”

Section: Clostridiummentioning

confidence: 99%

Foes or Friends? Bacteria Enriched in the Tumor Microenvironment of Colorectal Cancer

Yin

Zhang

et al. 2020

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third cause of cancer death in the world, while intestinal microbiota is a community of microbes living in human intestine that can potentially impact human health in many ways. Accumulating evidence suggests that intestinal microbiota, especially that from the intestinal bacteria, play a key role in the CRC development; therefore, identification of bacteria involved in CRC development can provide new targets for the CRC diagnosis, prevention, and treatment. Over the past decade, there have been considerable advances in applying 16S rDNA sequencing data to verify associated intestinal bacteria in CRC patients; however, due to variations of individual and environment factors, these results seem to be inconsistent. In this review, we scrutinized the previous 16S rDNA sequencing data of intestinal bacteria from CRC patients, and identified twelve genera that are specifically enriched in the tumor microenvironment. We have focused on their relationship with the CRC development, and shown that some bacteria could promote CRC development, acting as foes, while others could inhibit CRC development, serving as friends, for human health. Finally, we highlighted their potential applications for the CRC diagnosis, prevention, and treatment.

show abstract

Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota

Cited by 296 publications

References 82 publications

The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases

The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases

Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood

Foes or Friends? Bacteria Enriched in the Tumor Microenvironment of Colorectal Cancer

Contact Info

Product

Resources

About